biotx.ai and ViroStatics SRL announce partnership

biotx.ai and ViroStatics SRL partner up to develop CDK6 inhibitors for the treatment of acute respiratory distress syndrome (ARDS) and COVID-19

biotx.ai and ViroStatics SRL have signed a memorandum of understanding as the basis to jointly develop CDK6 inhibitors for ARDS. This will close major therapeutic gaps in the treatment of COVID-19 and better prepare the world for future SARS pandemics.

In 2021, biotx.ai discovered the driving mechanism behind critical illness from COVID-19, as well as the corresponding treatment (see our pre-print here). biotx.ai’s clinical phase 2b trial to show safety and efficacy of CDK6 inhibitors in hospitalized COVID-19 patients has been approved by the German Federal Institute for Drugs and Medical Devices and has commenced at the university hospital of Brandenburg, Germany. The goal of this trial is to show the utility of CDK6 inhibitors in the context of ARDS in general.

In order to develop more specialized CDK6 treatments, we have teamed up with ViroStatics SRL, a leading Italian biotech company. Together we will develop and investigate ViroStatics’ CDK6 inhibitor VS2-370. Early results are promising and we are optimistic that we will make major contributions to the development of drugs against all COVID-19 variants, future SARS pandemics, and ARDS.